Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.50 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.49 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22874527 | 0.84 | EGFR (0.55) | EGFRERBB2MRGPRX4ERBB3ERBB4 | |
| SCHEMBL25648997 | 0.84 | EGFR (0.55) | EGFRERBB2MRGPRX4ERBB3ERBB4 | |
| SCHEMBL156718 | 0.82 | MAOB (0.61) | EGFRERBB2MRGPRX4ERBB3ERBB4 | |
| SCHEMBL5312817 | 0.82 | EGFR (0.54) | EGFRERBB2MRGPRX4ERBB3ERBB4 | |
| SCHEMBL29514868 | 0.82 | MAOB (0.61) | EGFRERBB2MRGPRX4ERBB3ERBB4 | |
| SCHEMBL24388658 | 0.82 | CYP1A2 (0.61) | EGFRERBB2GAKMAOB | |
| SCHEMBL11910290 | 0.82 | MRGPRX4 (0.64) | EGFRERBB2MRGPRX4ERBB3ERBB4 | |
| SCHEMBL18805044 | 0.82 | MRGPRX4 (0.64) | EGFRERBB2MRGPRX4ERBB3ERBB4 | |
| SCHEMBL29388015 | 0.82 | MAOB (0.61) | EGFRERBB2MRGPRX4ERBB3ERBB4 | |
| SCHEMBL29434222 | 0.81 | MEN1 (0.60) | EGFRERBB2MRGPRX4MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | EGFR 4/4885ERBB2 1/4885MRGPRX4 1362/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885MRGPRX4 1072/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | EGFR 2/4885ERBB2 1/4885MRGPRX4 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.